论文部分内容阅读
目的:研究索拉非尼对伴有微血管侵犯（MVI）的肝内胆管细胞癌（ICC）患者术后缺氧诱导因子（HIF-1）、血管内皮生长因子（VEGF）水平及复发率的影响。方法:选择义乌市中心医院2013年11月至2019年11月就诊的ICC患者92例为观察对象，采用随机数字表法将其分为对照组和研究组，每组46例。对照组采用常规基础治疗，研究组在对照组的基础上加用索拉非尼治疗。比较两组患者临床疗效与治疗前后HIF-1、甲胎蛋白（AFP）、VEGF水平变化；比较两组患者不良反应发生情况和复发率。结果:治疗后，研究组总有效率［63.04%（29/46）］高于对照组［28.26%（13/46）］（χn 2=11.215，n P0.05），研究组患者HIF-1［（165.23±39.67）pg/mL］、AFP［（109.16±67.31）ng/mL］、VEGF［（297.28±42.41）pg/mL］水平均低于对照组［（205.56±40.23）pg/mL、（235.17±106.41）ng/mL、（365.16±40.91）pg/mL］（n t=4.841、6.788、7.813，均n P0.05）；随访6个月，研究组患者复发率低于对照组（χn 2=4.792，n P<0.05）。n 结论:索拉非尼可降低伴有MVI的ICC患者术后HIF-1、AFP、VEGF水平，提高临床疗效，且不增加不良反应发生率，降低复发率。“,”Objective:To investigate the effects of sorafenib on hypoxia inducible factor-1 (HIF-1) and vascular endothelial growth factor (VEGF) levels and recurrence in patients with intrahepatic cholangiocarcinoma with microvascular invasion.Methods:Ninety-two patients with intrahepatic cholangiocarcinoma who received treatment in Yiwu Central Hospital between November 2013 and November 2019 were included in this study. They were randomly assigned to undergo either conventional basic treatment (control group, n n = 46) or conventional basic treatment and sorafenib treatment (study group, n n = 46). Clinical efficacy, the incidence of adverse reactions and recurrence rate were compared between the two groups. Before and after treatment, HIF-1, alpha fetoprotein (AFP) and VEGF levels were also compared between the two groups.n Results:After treatment, total effective rate in the study group was significantly higher than that in the control group [63.04% (29 /46) n vs. 28.26% (13/46), n χ2 = 11.215, n P 0.05). After treatment, HIF-1 [(165.23 ± 39.67) pg/mL], AFP [(109.16 ± 67.31) ng/mL] and VEGF [(297.28 ± 42.41) pg/mL] levels in the study group were significantly lower than those in the control group [(205.56 ± 40.23) pg/mL, (235.17 ± 106.41) ng/mL, (365.16 ± 40.91) pg/mL, n t = 4.841, 6.788, 7.813, all n P 0.05). Six-month follow-up revealed that the incidence of recurrence in the study group was significantly lower than that in the control group ( n χ2 = 4.792, n P < 0.05).n Conclusion:Sorafenib can reduce the HIF-1, AFP and VEGF levels in patients with intrahepatic cholangiocarcinoma with microvascular invasion, improve the clinical efficacy, decrease the incidence of recurrence, but cannot increase the incidence of adverse reactions.